Alkermes Files Drug App With FDA

Xconomy Boston — 

Alkermes (NASDAQ: ALKS), the Waltham, MA-based biotech company, is announcing today it has filed an application with the FDA to start marketing a long-lasting version of naltrexone (Vivitrol) for people who are addicted to opioid-based narcotics. The Alkermes treatment, a once-monthly injection, is already approved by the FDA for treating alcohol dependence. Alkermes has asked the FDA for a faster-than-usual six-month review of its new application.